Table 2 Safety*
|  | CZP + MTX (n = 39) | CZP (n = 43) |
|---|---|---|
Total patients with ≥ 1 AE | 7 (17.9) | 5 (11.6) |
AE | 8 (19.5) | 5 (11.6) |
SAE | 0 (0) | 0 (0) |
Gastrointestinal disorders | 1 (2.4) | 0 (0) |
Infections and infestations | 2 (4.9) | 2 (4.7) |
COVID-19 | 2 (4.9) | 2 (4.7) |
Injury, poisoning, and procedural complications | 0 (0) | 1 (2.3) |
Investigations | 1 (2.4) | 0 (0) |
Musculoskeletal and connective tissue disorders | 2 (4.9) | 0 (0) |
Renal and urinary disorders | 1 (2.4) | 0 (0) |
Respiratory, thoracic, and mediastinal disorders | 1 (2.4) | 0 (0) |
Skin and subcutaneous tissue disorders | 0 (0) | 2 (4.7) |